Horizon Pharma plc June 15th Short Interest Update

Horizon Pharma plc (NASDAQ:HZNP), A drop of 1,522,401 shares or 8.8% was seen in the short interest of Horizon Pharma plc. Even as the interest dropped from 17,330,293 shares on May 31,2016 to 15,807,892 shares on June 15,2016, the days to cover came in at 5. The updated interest stood at 11.1% of the stocks floats. The stock has seen an average daily volume of 3,146,869 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Horizon Pharma plc (NASDAQ:HZNP): The stock opened at $16.64 on Friday but the bulls could not build on the opening and the stock topped out at $17.37 for the day. The stock traded down to $16.01 during the day, due to lack of any buying support eventually closed down at $16.25 with a loss of -6.82% for the day. The stock had closed at $17.44 on the previous day. The total traded volume was 23,493,361 shares.

The company shares have dropped -51.27% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $39.49 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $16.38 and the 200 Day Moving Average price is recorded at $17.37.

Horizon Pharma plc (NASDAQ:HZNP) has tumbled 1.87% during the past week and has dropped 2.11% in the last 4 week period. The stocks have underperformed the S&P 500 by 0.24% during the past week but Horizon Pharma plc (NASDAQ:HZNP) it has outperformed the index in 4 weeks by 0.85%.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *